Decellularization technology developer MiroMatrix Medical raised $23 million in a new round of equity financing, according to an SEC filing posted last week.
MiroMatrix develops and utilizes a proprietary technology to remove cells, or decellularize, organs and tissue.
Currently, MiroMatrix has 510(k) clearance for its MiroMesh biological mesh used during hernia repair procedures and as a general wound treatment, and plans to submit additional applications for other indications, according to its website.
MiroMatrix plans to pursue other applications of its proprietary technology, including creating a cortical strut, cardiac patch and other regenerative uses, according to the Eden Prairie, Minn.-based company’s site.
The round saw participation form 116 unnamed investors, according to an SEC filing. The company did not indicate if any returning investors cooperated in the round.
